Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00835354 · ClinicalTrials.gov registry record · Phase 1
Cefprozil for Oral Suspension 250 mg/5 mL, Non-fasting
A Phase 1 study, sponsored by Teva Pharmaceuticals USA.
- Completed
- Registry status
- Phase 1
- Development phase
- 26
- Enrollment target
NCT00835354: Completed Phase 1 study, sponsored by Teva Pharmaceuticals USA.
NCT00835354 is a Phase 1 study that has completed, run by Teva Pharmaceuticals USA. The registered enrollment target is 26 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00835354, a Phase 1 study, has completed, sponsored by Teva Pharmaceuticals USA.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 26 participants
- Enrollment target
Study Summary
The objective of this study is to compare the relative bioavailability of cefprozil for oral suspension 250 mg/5 mL (TEVA Pharmaceuticals USA) with that of CEFZIL® for Oral Suspension 250 mg/5 mL (Bristol-Myers Squibb) in healthy, non-smoking adults under non-fasting conditions.
Interventions
- DRUG Cefprozil for oral suspension 250 mg/5 mL
- DRUG CEFZIL® for Oral Suspension 250 mg/5mL
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 26 participants |
| Start Date | 2004-05 |
| Est. Completion | 2004-05 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00835354
The ClinicalTrials.gov registry entry for NCT00835354 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 26 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Teva Pharmaceuticals USA, which has 83 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Cefprozil for oral suspension 250 mg/5 mL is the first listed.
NCT00835354 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00835354 about?
NCT00835354 is a clinical study titled "Cefprozil for Oral Suspension 250 mg/5 mL, Non-fasting". The objective of this study is to compare the relative bioavailability of cefprozil for oral suspension 250 mg/5 mL (TEVA Pharmaceuticals USA) with that of CEFZIL® for Oral Suspension 250 mg/5 mL (Bristol-Myers Squibb) in healthy, non-smoking adults under non-fasting conditions.
What is the current status of trial NCT00835354?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 26 participants. The study started on 2004-05. Estimated completion is 2004-05.
What interventions are being tested in trial NCT00835354?
The interventions under investigation include: Cefprozil for oral suspension 250 mg/5 mL (DRUG), CEFZIL® for Oral Suspension 250 mg/5mL (DRUG).
Who is sponsoring clinical trial NCT00835354?
This trial is sponsored by Teva Pharmaceuticals USA, which has 83 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.